Format

Send to

Choose Destination
Curr Opin Oncol. 2013 May;25(3):224-8. doi: 10.1097/CCO.0b013e32835ff44b.

Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature.

Author information

1
Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Abstract

PURPOSE OF REVIEW:

Anaplastic thyroid cancer (ATC) is a rare and deadly malignancy. There is a need to speed up and support clinical research. This review article focuses on the new molecules that have been developed for the treatment of this aggressive tumor.

RECENT FINDINGS:

Improvement in the knowledge of pathogenesis and genetics of ATC led to the development of a variety of new molecules that may be used to treat this disease. In summary, these molecules are proteasome inhibitors, Aurora kinase inhibitors, vascular targeting agents, and gene therapies. All these molecules demonstrated a potentially therapeutic activity in metastatic ATC. To date, the largest prospective randomized multicenter, open-label, trial was conducted with combretastatin-A4.

SUMMARY:

More efficient drugs need to be developed through multinational efforts.

PMID:
23493194
DOI:
10.1097/CCO.0b013e32835ff44b
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center